Introduction

Renal transplantation is considered the optimal treatment modality for many individuals with end-stage renal failure. Access to transplantation is limited by the availability of appropriate donor organs and remains a major constraint. From 2009 to 2019, Australian organ donation rates increased from 11.3 to 21.6 donors per million population. This growth is partly attributable to changes in legislation permitting organ donation after circulatory death (DCD) and an increasing acceptance of older and comorbid donors—trends observed in many transplant jurisdictions.

With increasing variability in donor demographics, comorbidities, and perimortem physiology, the introduction of the Kidney Donor Risk Index (KDRI), a metric derived from ten donor variables associated with allograft failure, provided transplant physicians in the United States with some clarity when assessing the relative quality of donor kidneys. The utility of the KDRI, and its practical application, the Kidney Donor Profile Index (KDPI), was acknowledged through its integration into the US Kidney Allocation System in 2014 and is reflected in its use as a comparator across study populations in the literature. Clinically relevant variations are observed in the distribution of US-based KDRI/KDPI values against non-US study.

Background. The reporting of a locally validated kidney donor profile index (KDPI) began in Australia in 2016. Across diverse populations, KDPI has demonstrated utility in predicting allograft survival and function. A metric that incorporates both elements may provide a more comprehensive picture of suboptimal recipient outcomes. Methods. A retrospective cohort study of adult kidney transplant recipients in Australia (January 2009 to December 2014) was conducted. Conventional recipient outcomes and a composite measure of suboptimal outcome (1-y allograft failure or estimated glomerular filtration rate [eGFR] <30 mL/min) were evaluated across KDPI intervals (KDPI quintiles and 5-point increments in the KDPI 81–100 cohort). The impact of increasing KDPI on allograft function (1-y eGFR) and a suboptimal outcome was explored using multivariable regression models, adjusting for potential confounding factors. Results. In 2923 donor kidneys eligible for analysis, median KDPI was 54 (interquartile range [IQR], 31–77), and Kidney Donor Risk Index was 1.39 (IQR, 1.03–1.67). The median 1-y eGFR was 52.74 mL/min (IQR, 40.79–66.41 mL/min). Compared with the first quintile reference group, progressive reductions in eGFR were observed with increasing KDPI and were maximal in the fifth quintile (adjusted β-coefficient: −27.43 mL/min; 95% confidence interval, –29.44 to –25.42; P < 0.001). A suboptimal outcome was observed in 359 recipients (12.3%). The adjusted odds for this outcome increased across quintiles from a baseline of odds ratio of 1.00 (first quintile) to odds ratio of 11.68 (95% confidence interval, 6.33-21.54, P < 0.001) in the fifth quintile cohort. Conclusions. Increases in donor KDPI were associated with higher probabilities of a suboptimal outcome and poorer baseline allograft function, particularly in the KDPI > 80 cohort. These findings may inform pretransplant discussions with potential recipients of high-KDPI allografts.

Beyond Graft Survival: A National Cohort Study Quantifying the Impact of Increasing Kidney Donor Profile Index on Recipient Outcomes 1 Year Post-transplantation

Emma K. Tully, MBBS, BMedSci, FRACS,1,2 Ian P. Hayes, MBBS, MS, MEp, FRACS, FRCS,1,3 Peter D. Hughes, MBBS, FRACP, PhD,2,4 and Matthew P. Sypek, MBBS, FRACP, PhD2,4,5

Received 21 January 2022.
Accepted 29 January 2022.

1 Department of General Surgical Specialties, The Royal Melbourne Hospital, Parkville, VIC, Australia.
2 Department of Nephrology, The Royal Melbourne Hospital, Parkville, VIC Australia.
3 Department of Surgery, The University of Melbourne, Melbourne, VIC Australia.
4 Department of Medicine, The University of Melbourne, Melbourne, VIC Australia.
5 Australia and New Zealand Dialysis and Transplant Registry, SA Health and Medical Research Institute, Adelaide, SA, Australia.

The authors declare no funding or conflicts of interest.

E.K.T. participated in research design, in the writing of the article, in the performance of the research, and in data analysis. I.P.H. participated in research design and in data analysis. P.D.H. and M.P.S. participated in research design and in the writing of the article.

Correspondence: Emma K. Tully, MBBS, BMedSci, FRACS, Department of General Surgical Specialties, The Royal Melbourne Hospital, Level 6 East, 300 Grattan St, Parkville, VIC 3050 Australia. (emma.tully@mh.org.au).

Copyright © 2022 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

ISSN: 2373-8731
DOI: 10.1097/TXD.0000000000001308

(Transplantation Direct 2022;8: e1308; doi: 10.1097/TXD.0000000000001308).
populations, reflecting broad variability in the characteristics of donor pools across regions. Authors of European studies advocate for the development of KDRI algorithms tailored to local demographics, retrieval practices, and outcome data. In Australia a local KDRI/KDPI model (a derivation of the US model via exclusion of hepatitis C status and ethnicity) was validated in 2015, reported alongside organ offers from late 2016, and incorporated in allocation algorithms in April 2020.

Although KDRI/KDPI algorithms are based on the cumulative risk of allograft failure, multiple authors have quantified the intuitive association between increasing KDPI and poorer allograft function. Pruett et al argue that failure to achieve sufficient function from transplantation (defined as estimated glomerular filtration rate [eGFR] >30 mL/min/1.73 m² post-transplantation) may negate survival benefits to recipients over remaining on dialysis. Beyond this, impaired allograft function (1-y eGFR <30 mL/min) has been associated with other important recipient outcomes, including increased rates of hospitalization, post-transplant interventions, infection and cardiovascular morbidity and mortality.

From this perspective, the predominant reporting of hard outcomes, such as recipient and allograft survival, masks other outcomes that are important for recipients. In a review from the transplant division of the US National Surgical Quality Improvement Program, Amara et al noted that reporting allograft survival alone “fails to capture the impact of poorly functioning grafts and overestimates the success of renal transplant” and proposed a composite outcome measure incorporating recipient death, allograft failure, and poor function.

The study aimed to expand the evidence-base for a range of transplantation outcomes referenced to KDPI, with a specific focus on high-KDPI allografts, to inform pretransplant discussions with potential recipients. In our Australian renal transplant population, we aim to (1) examine and compare recipient outcomes across increasing KDPI strata through the lens of accepted outcome measures and a composite measure of suboptimal outcome—defined as allograft failure (death-censored) or eGFR <30 mL/min/1.73 m² post-transplantation and (2) determine the magnitude of the impact of increasing KDPI on both graft function (eGFR 1 y post-transplantation) and suboptimal outcome, adjusting for clinically relevant donor, recipient, and immunological factors.

**MATERIALS AND METHODS**

We performed a retrospective cohort study considering all deceased donor kidneys transplanted into adult recipients in Australia from January 2009 to December 2014. This time period was chosen to reflect contemporary donor demographics while avoiding a potential KDPI-labeling bias. Matched deidentified data were accessed from the Australian and New Zealand Dialysis and Transplant Registry and the Australian and New Zealand Organ Donor Registry. Donor-recipient pairs were excluded from analysis if (1) the procedure occurred as multiorgan, en bloc, or dual kidney transplant, (2) there was insufficient data to calculate donor KDRI, (3) recipients were lost to follow-up within 1 y of transplantation, or (4) 1 y eGFR was not recorded. Donation after circulatory death was practiced for the entirety of the study period, machine perfusion was not available, and all recipients had access to medicare-funded immunosuppression.

For each donor, KDRI was calculated retrospectively according to the Australian model, and KDPI was assigned with reference to the Australian donor kidney population from 2016 to 2018 (first available reference period). KDPI risk strata were designated as follows: first quintile (lowest risk): KDPI 1–20; second quintile: KDPI 21–40; third quintile: KDPI 41–60; fourth quintile: KDPI 61–80; and fifth quintile (highest risk): 81–100. To investigate the outcome of transplants with the highest-risk allografts in finer detail, the fifth quintile was subdivided at KDPI 5-point increments.

Data were collected across donor and recipient demographics, comorbid conditions, immunological matching parameters, pre-terminal donor management, and post-procurement events (Table 1; definitions, Table S1, S DC, http://links.lww.com/)

**Table 1.** Variables examined in this study (excluding those directly involved in the calculation of KDRI)

| Variable                        | Management | Reported Units |
|---------------------------------|------------|----------------|
| Outcome variables               |            |                |
| eGFR                            | Continuous | mL/min/1.73 m² |
| Suboptimal outcome              | Binary     | Yes = 1        |
| Donor factors                   |            |                |
| Donor gender                    | Binary     | Male = 1       |
| Donor smoking history           | Binary     | Yes = 1        |
| Donor CPR                       | Binary     | Yes = 1        |
| Donor inotropes                 | Binary     | Yes = 1        |
| Donor oliguria                  | Binary     | Yes = 1        |
| Procurement factors             |            |                |
| Transplant out of region        | Binary     | Yes = 1        |
| Procurement biopsy              | Binary     | Yes = 1        |
| Ischemic time                   | Binary     | Ischemic time >12 h = 1 |
| Immunological factors           |            |                |
| HLA mismatch                    | Continuous | Total number HLA mismatches (0–6) |
| PRA                             | Continuous | Maximum recorded cPRA (0–100) |
| Recipient factors               |            |                |
| Recipient gender                | Binary     | Male = 1       |
| Recipient age                   | Continuous | Years          |
| Dialysis years                  | Continuous | Years          |
| <1 y                            | Binary     | Yes = 1        |
| 1–10 y                          | Binary     | Yes = 1        |
| >10 y                           | Binary     | Yes = 1        |
| Previous transplant/s           | Binary     | Yes = 1        |
| Etiology renal disease          | Binary     |                |
| High-risk GN                    | Yes = 1    |                |
| Recipient BMI                   | Continuous | kg/m²          |
| <25 kg/m²                       | Binary     | Yes = 1        |
| 25–30 kg/m²                     | Binary     | Yes = 1        |
| >30 kg/m²                       | Binary     | Yes = 1        |
| Recipient smoking history       | Binary     | Yes = 1        |
| CAD                             | Binary     | Yes = 1        |
| PVD                             | Binary     | Yes = 1        |
| CVA                             | Binary     | Yes = 1        |
| Recipient diabetes              |            |                |
| T2DM                            | Binary     | Yes = 1        |
| T1DM                            | Binary     | Yes = 1        |

*Transplant regions in Australia: (1) Queensland, (2) New South Wales/Australian Capital Territory, (3) Victoria/Tasmania, (4) South Australia/Northern Territory, and (5) Western Australia. BMI, body mass index; CAD, coronary artery disease; CPR, cardiopulmonary resuscitation; cPRA, calculated panel reactive antibody; CVA, cerebrovascular accident; eGFR, estimated glomerular filtration rate; GN, glomerulonephropathy; KDRI, Kidney Donor Risk Index; PRA, panel reactive antibody; PVD, peripheral vascular disease; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.
TXD/A409). In addition to previous associations with graft outcomes, these variables were chosen to reflect data reasonably available or approximated before transplantation. Study variables were compared across KDPI cohorts (assuming a non-normal distribution) using the Kruskal-Wallis test by ranks for continuous variables, and Pearson chi-squared test for categorical variables. Differences were considered statistically significant at $P < 0.05$.

The primary outcomes in this study were (1) recipient serum eGFR (Modification of Diet in Renal Disease [relating to the equation used to calculate eGFR]) measured at 1 y post-transplant (1-y eGFR) and (2) suboptimal outcome, defined as death-censored graft failure or eGFR <30 mL/min at the time point 1 y post-transplant. Allograft failure was considered to have occurred if recipients returned to dialysis, or recorded 1-y eGFR <10 mL/min. Across KDPI quintiles, 1-y eGFR was reported as both median eGFR and proportions of recipients falling into each category of renal impairment defined by the Kidney Disease Improving Global Outcomes chronic kidney disease (CKD) classification (2009).16

Secondary outcome measures in this study were allograft failure and recipient death at 1 and 5 y post-transplantation. Event rates were reported for delayed graft function and allograft rejection (treated episodes) within 1 y of transplantation. Outcome measures were reported for the entire study cohort, each KDPI quintile, and across 5-point increments in the fifth quintile.

Multivariable regression analyses were performed across the KDPI 1-100 population and in the fifth quintile cohort to determine the effect of increasing KDPI on 1-y eGFR (linear regression) and suboptimal outcome (logistic regression). The effect of increasing KDPI (quintile or 5-point increment) was documented against a baseline comparator group (first quintile or KDPI 81–85) and expressed as reductions in 1-y eGFR (mL/min) or odds ratio (OR; odds of suboptimal outcome) in the nominated group compared to the baseline group. Clinically relevant donor, recipient, immunological, and procurement variables identified as having a potential association with an outcome on univariate analysis ($P < 0.20$) were included in the multivariable analysis for the outcome. Multivariable regression analyses were performed using backward stepwise elimination (exclusion $P > 0.05$). Interaction terms were created and tested for clinically relevant variables. Regression diagnostic procedures were used to identify and examine outliers and high-leverage data points, define nonlinear relationships, and correct variable misspecifications. In each analysis, initial models were constructed using a continuous KDPI variable and compared to a model restricted to the KDPI interval variable (quintiles or 5-point increases) via likelihood ratio testing. Within the logistic regression models, sufficient power was maintained with event-to-variable ratios >10.

This study was approved by the Melbourne Health Human Research Ethics Committee (MH2020.170). Statistical analyses were conducted using Stata 16 MP software (StataCorp, College Station, TX).
RESULTS

Of the 3095 adult recipients of deceased donor kidneys identified within the study period, 37 were excluded because of insufficient data for KDRI calculations, 72 were excluded as recipients of dual or en bloc transplants, and 57 were excluded because the 1-y eGFR was not available. Six recipients were lost to follow-up within 12 mo of transplantation, leaving 2923 donor-recipient pairs (94.4%) eligible for analysis.

Study Population

In this donor population, the median KDPI was 54 (interquartile range, 31–77), and median KDRI was 1.39 (interquartile range, 1.03–1.67). A KDRI of 1.00 and a KDRI of 2.00 mapped to a KDPIs of 27 and 89, respectively (Figure 1). An increase in the gradient of a line plotting the median KDRI against KDPI is observed from the KDPI 81–85 mark, indicating a larger increase in donor risk per KDPI interval from this point.

The summary statistics for the donor variables contributing to KDRI calculations are presented in Table 2. The median donor age increased progressively with KDPI, coarsely dictating KDPI quintile. Differences in the proportions of donors with hypertension, stroke, and diabetes were progressive and marked from the first to fifth quintiles, whereas differences between quintiles for other KDRI component variables (DCD pathway, height, weight, and terminal creatinine) were less consistent. Similar trends continued into the fifth quintile, with increasing terminal creatinine and a decreasing proportion of DCD donors observed across this cohort.

The summary statistics for donor, recipient, procurement, and immunological matching variables not included in the calculation of KDRI are presented in Tables S2 and S2, SDC, http://links.lww.com/TXD/A409. Consistent and clinically relevant differences across quintiles were noted in the proportion of male donors (decrease across quintiles), incidence of donor cardiopulmonary resuscitation (increase), procurement biopsy (increase), median recipient age (increase), duration of dialysis (increase), and incidence of coronary artery disease and type 2 diabetes mellitus in recipients (increase). In the fifth quintile study population, the only significant trend was an increase in the incidence of procurement biopsies.

The proportion of missing data across the study variables was greatest for panel reactive antibody (4.5%), ischemic time (3.7%), and recipient body mass index (3.0%). As a review of missing data revealed no discernible patterns or relationships with outcomes, regression analyses were carried performed as complete case analyses.

Primary Outcomes

Graft Function—1-Y eGFR

The median 1-y eGFR for recipients with a functioning graft was 52.74 mL/min, which decreased with each increment in KDPI quintile (Figure 2, Table 3). Figures 3A and 3B and Table 4 demonstrate the distribution of 1-y eGFR across KDPI quintiles and 5-point increments (fifth quintile allografts). The difference in the proportions of recipients with stage II CKD (mild impairment) and stage IV CKD (severely decreased renal function) was marked across quintiles. Across the fifth quintile, a notable increase in the...
The proportion of recipients with stage IV renal impairment was observed.

Univariate linear regression analysis (dependent variable 1-\text{y eGFR}) revealed a strong negative correlation between the increasing KDPI quintile and 1-\text{y eGFR} when comparing recipients in the second to fifth quintiles (\(\beta\)-coefficients: −9.48 to −28.86 mL/min) against the first quintile group (constant 70.24 mL/min) (Table S4, SDC, http://links.lww.com/TXD/A409). An initial multivariable linear regression model was constructed expressing KDPI as a continuous variable and carrying forward variables identified as potential confounders on univariate analysis (Table 5). Regression diagnostics revealed a normal distribution of residuals. There was no evidence of multicollinearity among the included variables or of clinically or statistically significant interactions between variables. High-eGFR data points had significant leverage and were influential. Thus, population eGFR values were capped at 90 mL/min.

Within the final model, each single-point increase in KDPI resulted in a 0.33 mL/min decrease in eGFR. A nested model restricted to KDPI quintiles did not differ from the initial continuous KDPI model (likelihood ratio test \(\chi^2\) [3] = −31.95, \(P = 1.00\)). Within the restricted model, adjusted decreases in eGFR across KDPI quintiles ranged from 8.76 mL/min (second quintile) to 27.43 mL/min (fifth quintile), based on a first quintile (constant) eGFR of 70.35 mL/min (Table 5). The final models with KDPI expressed as a continuous or categorical (quintile) variable (\(R^2 = 0.31\), accounted for more outcome variability than KDPI (\(R^2 = 0.29\), \(\beta\)-coefficient, −0.36 mL/min/KDPI) and donor age (\(R^2 = 0.25\), \(\beta\)-coefficient −0.56 mL/min/y) alone.

Increases in KDPI across the fifth quintile cohort were also associated with a decrease in 1-\text{y eGFR} on univariate analysis. In this smaller population, a statistically sound multivariable linear regression model based on clinically relevant variables could not be constructed, and we reported the unadjusted effect of increasing KDPI in this quintile (Table 5).

Suboptimal 1-Year Outcome: Graft Failure or eGFR <30 mL/min

One year post-transplant, 359 recipients (12.3% of the study population) had either a failed allograft or serum eGFR <30 mL/min. The incidence of this suboptimal outcome increased progressively across KDPI quintiles, reaching 41.6% in allografts with KDPI >95 (Table 3). Using first quintile recipients as a comparator group, univariate logistic regression suggested a strong correlation between increasing KDPI quintile and suboptimal outcome, ranging from OR, 2.56 (95% confidence interval [CI], 1.33-4.91; \(P = 0.005\)) in the second quintile to OR, 12.96 (95% CI, 7.26-23.15; \(P < 0.001\)) in the fifth quintile (Table S4, SDC, http://links.lww.com/TXD/A409).
TABLE 3. One-Year primary outcomes across KDPI quintiles in the total study population, and 5-point intervals in the fifth quintile cohort

| Fifth quintile cohort | KDPI 81–85 | KDPI 91–95 | KDPI 96–100 | KDPI 100–105 |
|-----------------------|------------|------------|-------------|--------------|
| Total study population| 192        | 166        | 106         | 63           |
| n                     | 105        | 87         | 52          | 33           |
| Transplantation (mL/min) (IQR) | 0.03 (0.00-0.06) | 0.09 (0.05-0.13) | 0.15 (0.10-0.20) | 0.23 (0.10-0.42) |
| Δn (mL/min) (IQR) | -0.04 (-0.07 to -0.01) | -0.06 (-0.09 to -0.03) | -0.08 (-0.10 to -0.06) |
| P                   | <0.001     | <0.001     | <0.001      | 0.63         |
| Suboptimal outcome (%) | 359 (11)  | 13 (4)     | 35 (7)      | 65 (10)      |
| P                   | <0.001     | <0.001     | <0.001      | 0.003        |
| Adjusted probability: (95% CI) | 0.09 (0.05-0.11) | 0.00 (0.00-0.02) | 0.00 (0.00-0.00) |

Inclusion of potential confounders in a multivariable logistic regression model for suboptimal outcome resulted in slight downward adjustment of ORs for each KDPI quintile (Table 6). The predicted probability of a suboptimal outcome using this model (covariates at means) ranged from 0.03 in the first quintile to 0.25 in the fifth quintile. This model was built using a continuous KDPI variable requiring a nonlinear transformation (KDPI \(> 2.99\)) and an interaction term (type 2 diabetes mellitus and peripheral vascular disease). High-leverage data points, typically observed in recipients with high panel reactive antibody and longer dialysis duration, had low residual values, and were not influential. Exploration of the high residual values observed in recipients with suboptimal outcome and low predicted probability often identified an association with post-transplant events (surgical complications or allograft rejection). The final model had a moderate discriminatory capacity (area under curve \(= 0.75\)) and fit the data well (Hosmer-Lemeshow Test \(\chi^2 [8] = 8.38, P = 0.40\)). A nested model restricted to KDPI quintiles did not significantly differ from the continuous KDPI model (likelihood ratio test \(\chi^2 [3] = -21.44, P = 1.00\)).

Within the fifth quintile, associations between rising KDPI and an increasing incidence of suboptimal outcome remained strong, although nonsignificant in the KDPI 86–90 interval. Slight reductions in these ORs were observed after adjustment using multivariable logistic regression (Table 6).

Secondary Outcomes

Delayed graft function was observed in 915 recipients (32.0%), and 688 recipients (23.5%) were treated for allograft rejection in the first year after transplantation (Table 7). When compared to allografts from donors with KDPI <80, fifth quintile allografts were associated with increased odds of delayed graft function (unadjusted OR, 1.69; 95% CI, 1.40-2.04; \(P < 0.001\)) and rejection (unadjusted OR, 1.37; 95% CI, 1.11-1.68; \(P = 0.002\)).

In this study, 111 recipients (3.8%) had documented allograft failure 1 y post-transplant. The odds of this outcome were higher in the fifth quintile than in the rest of the population (unadjusted OR, 2.35, 95% CI, 1.54-3.54, \(P < 0.001\)). The incidence of death within 1 y of transplantation was 2.5% (74 recipients), without notable trends across quintiles.

In recipients with a functioning allograft and 1-y eGFR <30 mL/min (248 recipients, 8.5% of the study population), 64 (25.8%) progressed to allograft failure and 37 recipients (14.9%) died within 5 y of transplantation (3 lost to follow-up, 5-y eGFR not recorded for 27 recipients). Compared with recipients with 1-y eGFR >30 mL/min (2504 recipients, 4.2% allograft failure, 7.2% deceased at 5 y), those with 1-y eGFR <30 mL/min had higher odds of allograft failure (unadjusted OR, 8.16; 95% CI, 5.67-11.67; \(P < 0.001\)) and death (unadjusted OR, 2.27; 95% CI, 1.50-3.35; \(P < 0.001\)) at 5 y post-transplant.

DISCUSSION

The kidney donor profile index provides a standardized means of communicating allograft quality. Although multiple studies across diverse populations have documented the relationship between KDPI and allograft survival, few have
reported on the relationship between KDPI and allograft function. This study established a consistent and clinically relevant relationship between increasing donor KDPI and poorer allograft function (1-y eGFR) in our population. Using data from a national transplant registry, this study considers the composite outcome of allograft failure and poor function, identifying significant associations between increasing KDPI and the odds of this suboptimal outcome.

A few single-center European studies have reported 1-y functional outcomes according to KDPI, although the reference intervals differ. German studies with comparable donor demographics (noting an absence of DCD donors), report similar median 1-y eGFR values over equivalent KDPI ranges (KDPI < 20: eGFR 65.8 mL/min; KDPI < 35: eGFR 65 mL/min; KDPI > 85: eGFR 39 mL/min).5,17 In Dahmen 580-patient cohort, multivariable regression analyses

---

**FIGURE 3.** Distribution of 1-y eGFR according to KDIGO Classification of Chronic Kidney Disease. Incidence across (A) KDPI quintiles and (B) 5-point increments in KDPI >80 allografts. KDIGO CKD stages: stage I—eGFR >90 mL/min; stage II—eGFR 60-90 mL/min; stage IIIa—eGFR 45–60 mL/min; stage IIIb—eGFR 30–45 mL/min; stage IV—eGFR 15–30 mL/min; stage V—eGFR <15 mL/min. CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; KDIGO, Kidney Disease Improving Global Outcomes; KDPI, Kidney Donor Profile Index.
were used to evaluate the utility of KDPI (against donor age) in predicting allograft function (1-y eGFR). In their models, recipient body mass index was the only additional variable that showed a significant association.5

In this study, adjustment for potentially confounding variables resulted in little change in the magnitude of the effect of KDPI in our models, adding minimal explanation of variation in our outcomes beyond KDPI alone. This suggests that of the information reasonably available prior to transplantation, donor KDPI is the key determinant of functional outcomes, with other factors having minimal impact or mediation of this effect. Intraoperative or post-transplant events, including surgical complications, delayed graft function, rejection episodes, immunosuppression regimen, patient compliance, and infection, were not considered in this study. Although these factors undoubtedly contribute to transplant outcomes, our purpose was to produce results using pretransplant data that could inform pretransplant discussions with recipients.

We report the incidence of donor characteristics across KDPI quintiles in the Australian population, noting that complex differences exist in the characteristics of donor populations worldwide. Compared with this study, large donor population studies based on US registry data consist of younger donors (median age 40 y), lower rates of DCD donation (15.2%), and considerably higher incidences of diabetes and hypertension across all KDPI ranges,18,19 Aside from the aforementioned German studies, European studies reporting donor characteristics according to KDPI are limited. A recent study by Pippias et al3 outlines significant variations in KDRI between select countries, ranging from KDRI 0.97 in Slovenia to 1.50 in the Basque region (in 2011), and wide-ranging proportions of DCD donors across Europe, from 0% in Slovenia and Denmark to 45% in the United Kingdom and 55% in the Netherlands (2015).

These examples highlight the hazards of drawing direct comparisons between populations using scaled KDPI or population-specific KDRI algorithms. In Pippias et al’s report, the median standardized KDRI (across all countries) increased by 13% over the 10-y study period (2005–2015). In an Australian population, Chan et al20 noted an increase in median KDRI (US algorithm) from 1.02 to 1.32 in the 20 y to 2013. Shifts in donor pool demographics, through alterations in donation practices or precipitated by events such as the coronavirus disease 2019 pandemic, will alter the actual risk (KDRI) represented by the donor KDPI (scaled risk). The perception of risk represented by KDPI values may require periodic recalibration.

Compared with allograft failure alone, the incorporation of allografts with severely impaired baseline function into a composite suboptimal outcome metric identified almost 3.5x more recipients for whom the results of transplantation were (perhaps) poorer than anticipated. In addition to allograft survival, poor allograft function after transplantation is a predictor of various morbidities in recipients. Meier-Kriesche et al published findings of progressive increases in the relative risks of both cardiovascular and infection-related death for transplant recipients with 1-y serum creatinine over 1.5 mg/dL (≈133 µmol/L).12 Lam et al21 note significant increases in the risk of myocardial infarction (hazard ratio, 1.85) and cardiovascular disease–related death (hazard ratio, 4.54) in transplant recipients

### Table 4.

| Distribution of eGFR according to KDIGO 2009 CKD classification, per KDPI quintile and 5-point intervals in the fifth quintile cohort |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                            | Total study population      | Fifth quintile cohort       | Total quintile               | Fourth quintile              | Third quintile               | Second quintile              | First quintile               | Total study population      | Fifth quintile cohort       |
|                            |                             | 105                        | 185                        | 165                        | 145                        | 125                        | 105                        | 95                         | 90                         |
| eGFR (mL/min/1.73 m²)      |                             | 192                        | 185                        | 178                        | 171                        | 164                        | 157                        | 150                        | 143                        |
| Functioning graft (%)      |                             | 2752 (94)                  | 2683 (94)                  | 2614 (94)                  | 2545 (94)                  | 2476 (94)                  | 2408 (94)                  | 2340 (94)                  | 2272 (94)                  |
| CKD stage (%)              |                             | 120 (4)                    | 119 (4)                    | 117 (4)                    | 115 (4)                    | 113 (4)                    | 111 (4)                    | 110 (4)                    | 109 (4)                    |
| I: >90 mL/min             |                             | 10 (0)                     | 10 (0)                     | 10 (0)                     | 10 (0)                     | 10 (0)                     | 10 (0)                     | 10 (0)                     | 10 (0)                     |
| II: 60–90 mL/min          |                             | 485 (17)                   | 373 (14)                   | 303 (12)                   | 244 (15)                   | 186 (15)                   | 132 (14)                   | 105 (13)                   | 80 (11)                    |
| IIIa: 45–60 mL/min        |                             | 484 (17)                   | 380 (13)                   | 302 (12)                   | 242 (15)                   | 189 (16)                   | 131 (14)                   | 102 (12)                   | 70 (10)                    |
| IIIb: 30–45 mL/min        |                             | 651 (24)                   | 498 (19)                   | 390 (15)                   | 321 (20)                   | 255 (24)                   | 196 (21)                   | 153 (17)                   | 102 (15)                   |
| IV: 15–30 mL/min          |                             | 235 (9)                    | 193 (7)                    | 150 (7)                    | 124 (9)                    | 101 (10)                   | 77 (8)                     | 57 (7)                     | 39 (6)                     |
| V: <15 mL/min             |                             | 7 (0)                      | 7 (0)                      | 7 (0)                      | 7 (0)                      | 7 (0)                      | 7 (0)                      | 7 (0)                      | 7 (0)                      |

CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; KDGO, Kidney Disease Improving Global Outcomes; KDPI, Kidney Donor Profile Index.
TABLE 5.
Adjusted coefficients for variables predicting recipient 1-y eGFR (mL/min) in the total study population, as per multivariable linear regression analyses, using models with (1) continuous KDPI predictor variable and (2) KDPI Quintile predictor variable

| Variable | KDPI (1–100) continuous* | KDPI quintiles |
|----------|---------------------------|---------------|
| KDPI     | Adjusted B-coefficient (95% CI) | P         | Adjusted B-coefficient (95% CI) | P       |
| KDPI quintile |                       |               | First quintile | 0         |               |
| Second quintile |                       |               |               | –0.34 (−0.36 to −0.31) | <0.001  |
| Third quintile |                       |               |               | –0.34 (−0.36 to −0.31) | <0.001  |
| Fourth quintile |                       |               |               | –0.34 (−0.36 to −0.31) | <0.001  |
| Fifth quintile |                       |               |               | –0.34 (−0.36 to −0.31) | <0.001  |
| Donor male | 2.35 (1.14–3.56) | <0.001 | 2.52 (0.94–4.23) | <0.001 |
| Donor CPR  | 2.10 (0.88–3.33) | 0.001 | 2.12 (0.89–3.36) | 0.001  |
| Transplant out of region | 2.77 (0.75–4.79) | 0.01 | 2.86 (0.82–4.89) | 0.01   |
| Ischemic time >12 h | –1.46 (−2.71 to −0.21) | 0.02 | –1.61 (−2.87 to −0.36) | 0.01   |
| Procurement biopsy | NS (P = 0.699) |               | NS (P = 0.699) |               |
| Donor CPR | 2.10 (0.88–3.33) | 0.001 | 2.12 (0.89–3.36) | 0.001  |
| Recipient age | –0.05 (−0.09 to −0.03) | <0.001 | –0.05 (−0.09 to −0.03) | <0.001 |
| Recipient BMI | NS (P = 0.932) |               | NS (P = 0.932) |               |
| <25 kg/m² | 0 |               | 0 |               |
| 25–30 kg/m² | –4.00 (−5.41 to −2.59) | <0.001 | –3.81 (−5.23 to −2.39) | <0.001 |
| >30 kg/m² | –6.51 (−8.06 to −4.97) | <0.001 | –6.36 (−7.92 to −4.80) | <0.001 |
| Previous transplant | 2.89 (0.85–4.93) | 0.01 | 2.92 (0.87–4.98) | 0.005  |
| Dialysis years | NS (P = 0.460) |               | NS (P = 0.460) |               |
| High-risk GN | NS (P = 0.118) |               | NS (P = 0.118) |               |
| Recipient smoking | NS (P = 0.066) |               | NS (P = 0.066) |               |
| Recipient CAD | NS (P = 0.729) |               | NS (P = 0.729) |               |
| Recipient T2DM | 2.55 (0.92–4.18) | 0.002 | 2.58 (0.94–4.23) | 0.002  |
| Constant | 73.08 (71.19–74.98) | <0.001 | 70.35 (68.33–72.37) | <0.001 |

*Adjusted for continuous predictor variables, model: total observations, 2485; P < 0.001.

†Refer to Table S1, SDC, http://links.lww.com/TXD/A409 for definition of variables; refer to Table S4, SDC, http://links.lww.com/TXD/A409 for a full list of B-coefficients on univariate analysis.

‡Entered as categorical variable.

BDI, body mass index; CAD, coronary artery disease; CI, confidence interval; CPR, cardiopulmonary resuscitation; eGFR, estimated glomerular filtration rate; GN, glomerulonephropathy; KDPI, Kidney Donor Profile Index; NS, nonsignificant; PRA, panel reactive antibody; T2DM, type 2 diabetes mellitus.

with eGFR <30 mL/min, whereas Karthikeyan et al report doubling of kidney failure complications below this threshold, noting marked increases in anemia and rates of uncontrolled hypertension.

It is plausible that the improved transparency of outcomes for high-KDPI kidneys afforded by this study might fuel risk-averse acceptance behaviors. The nonutilisation rate of retrieved kidneys in Australia, although low by international standards, is ≈10% (2019). In a review following the introduction of KDPI reporting in Australia, Sypek et al document a 45% increase in offer declines for high-risk kidneys (KDPI > 80), without an increase in nonutilisation in the postreporting period, suggesting the presence of a labeling effect and diversion of high-KDPI kidneys to older recipients. In the US study would be largely equivalent to those calculated using US KDRI formulae.

The interpretation of the results of this study involves some caveats. We utilized a retrospective methodology and national registry data, subject to error at individual entry points and restricted to data fields collected. As we consider only adult recipients and have donor and recipient populations that are predominantly Caucasian, caution should be exercised when extrapolating the results to pediatric and non-Caucasian recipients. Although the Australian KDRI is a derivation of the US algorithm, the incidence of US donor variables omitted from Australian KDRI calculations was low in our cohort (hepatitis C positive = 0.5%, African-American ethnicity = 0%), and thus, KDRI values in our study would be largely equivalent to those calculated using US KDRI formulae.

The dichotomization of outcomes based on eGFR at a single time point has inherent limitations. It does not consider patients with transiently impaired function (eg, acute rejection), and models based on the resultant binary outcome have impaired discriminatory capacity around the cutoff value. Furthermore, the individual facets of the composite outcome...
(graft failure versus 1-y eGFR <30) have different implications, and as a unified concept, it may be difficult to explain to potential recipients.

As organ donation agencies strive to maximize donation and transplant opportunities, high KDRI kidneys will continue to be offered. The optimal utility of this resource remains an important focus. Allocation algorithms with survival-matching protocols, alongside allowances for preemptive transplantation in older recipients, have demonstrated merit. Tullius et al. established that the risk of rejection in allografts from older donors is attenuated in older recipients—a benefit likely afforded through immunosenescence—whereas separate US studies have suggested that preemptive transplantation, in minimizing the accrued morbidity of dialysis, may offset risks associated with high-KDPI allografts in older recipients.25,28

Another important focus is risk minimization in high-KDPI allografts. Doshi et al. suggested that both procurement biopsies and machine perfusion are unreliable in predicting outcomes in the KDPI >80 population, are resource-intensive, and prolonged ischemic times. Alternatively, consideration of adjunct factors during donor evaluation may be valuable.

### Table 6

| Variable | Total study population | | | fifth quintile cohort | | |
|---|---|---|---|---|---|---|
| | Adjusted OR (95% CI) | P | Adjusted OR (95% CI) | P |
| KDPI quintile | | | | | | |
| First quintile | 1.00 | – | – | – |
| Second quintile | 2.33 (1.17-4.61) | 0.02 | – | – |
| Third quintile | 3.36 (1.77-6.37) | <0.001 | – | – |
| Fourth quintile | 4.57 (2.43-8.61) | <0.001 | – | – |
| Fifth quintile | 11.68 (6.33-21.54) | <0.001 | – | – |
| KDPI interval | | | | | | |
| 81–85 | – | – | 1.00 | – |
| 86–90 | – | – | 1.60 (0.92-2.78) | 0.10 |
| 91–95 | – | – | 2.60 (1.51-4.49) | 0.001 |
| 96–100 | – | – | 4.66 (2.60-8.36) | <0.001 |
| Donor male | NS (P = 0.172) | – | – | – |
| Donor CPR | 0.67 (0.51-0.88) | 0.004 | – | – |
| Inotropes | NS (P = 0.063) | – | NS (P = 0.374) | – |
| Oliguria | NS (P = 0.457) | – | – | – |
| Ischemic time >12 h | 1.39 (1.08-1.79) | 0.01 | NS (P = 0.270) | – |
| Procurement biopsy | NS (P = 0.090) | – | – | – |
| Transplant out of region | 0.41 (0.24-0.69) | 0.001 | NS (P = 0.225) | – |
| HLA mismatch | NS (P = 0.074) | – | 1.13 (1.00-1.27) | 0.05 |
| PRA | 1.01 (1.00-1.01) | 0.005 | – | – |
| Previous transplant | NS (P = 0.104) | – | – | – |
| Recipient age | 0.99 (0.98-1.00) | 0.02 | – | – |
| Recipient BMI <25 kg/m² | 1.00 | – | – | – |
| 25–30 kg/m² | 1.37 (1.01-1.86) | 0.04 | 1.45 (0.90-2.31) | 0.12 |
| >30 kg/m² | 1.59 (1.15-2.19) | 0.005 | 2.30 (1.41-3.76) | 0.001 |
| Dialysis years | | | | | | |
| <1 y | 0.56 (0.34-0.92) | 0.02 | – | – |
| 1–10 y | 1.00 | – | – | – |
| >10 y | 2.46 (1.28-4.72) | 0.01 | – | – |
| High risk GN | 1.71 (1.21-2.41) | 0.002 | 2.40 (1.37-4.24) | 0.002 |
| Recipient CAD | NS (P = 0.387) | – | – | – |
| Recipient PVD | 1.83 (1.17-2.87) | 0.01 | – | – |
| Recipient CVA | NS (P = 0.608) | – | NS (P = 0.138) | – |
| Recipient T2DM | 1.45 (1.02-2.08) | 0.04 | NS (P = 0.286) | – |
| Recipient smoking | NS (P = 0.192) | – | – | – |
| Interaction PVD/T2DM | 0.53 (0.25-1.11) | 0.09 | – | – |
| Constant | 0.04 (0.02-0.09) | <0.001 | 0.07 (0.04-0.14) | <0.001 |

aTotal study population model: observations: 2577; events: 353; event:variable = 29.4; model P < 0.001.

bFifth quintile model: observations: 585; events: 163; event:variable = 32.5; model P < 0.001.

cRefer to Table S1, SDC, http://links.lww.com/TXD/A409 for definition of variables; refer to Table S4, SDC, http://links.lww.com/TXD/A409 for a full list of odds ratios on univariate analysis.

dEntered as continuous variable.

eRecipient age did not meet inclusion criteria on univariate analysis (0.502); however, it was considered an important potential confounder on clinical grounds and was statistically significant within multivariable regression analysis. BMI, body mass index; CAD, coronary artery disease; CI, confidence interval; CPR, cardiopulmonary resuscitation; CVA, cerebrovascular accident; GN, glomerulonephropathy; NS, nonsignificant; OR, odds ratio; PRA, panel reactive antibody; PVD, peripheral vascular disease; T2DM, type 2 diabetes mellitus.
## Table 7

| Quintile cohort | KDPI < 70 | KDPI 71–75 | KDPI 76–80 | KDPI 81–85 | KDPI 86–90 | KDPI 91–95 | KDPI 96–100 |
|-----------------|-----------|------------|------------|------------|------------|------------|------------|
| Total           | 2386      | 698 (24)   | 87 (18)    | 12 (2)     | 12 (2)     | 15 (3)     | 3 (1)      |
| First quintile  | 252 (1)   | 21 (2)     | 15 (3)     | 5 (2)      | 5 (2)      | 7 (4)      | 4 (2)      |
| Second quintile | 207 (62)  | 112 (22)   | 13 (3)     | 13 (3)     | 12 (2)     | 18 (3)     | 3 (1)      |
| Third quintile  | 218 (65)  | 68 (22)    | 9 (2)      | 9 (2)      | 12 (2)     | 16 (3)     | 4 (2)      |
| Fourth quintile | 157 (53)  | 50 (16)    | 12 (2)     | 4 (1)      | 15 (3)     | 22 (3)     | 3 (1)      |
| Fifth quintile  | 149 (50)  | 47 (16)    | 17 (3)     | 17 (3)     | 18 (3)     | 25 (4)     | 6 (3)      |

| Delayed graft function (%) | n | n | n | n | n | n |
|----------------------------|---|---|---|---|---|---|
| 0–60 days                  | 19 | 1 | 2 | 1 | 1 | 0 |
| 61–180 days                | 3 | 3 | 6 | 1 | 0 | 2 |
| 181–365 days               | 1 | 1 | 6 | 1 | 0 | 2 |
| 366–730 days               | 1 | 1 | 6 | 1 | 0 | 2 |
| >730 days                  | 1 | 1 | 6 | 1 | 0 | 2 |

| Death (%)                  | n | n | n | n | n | n |
|----------------------------|---|---|---|---|---|---|
| 0–60 days                  | 3 | 3 | 6 | 1 | 0 | 2 |
| 61–180 days                | 1 | 1 | 6 | 1 | 0 | 2 |
| 181–365 days               | 1 | 1 | 6 | 1 | 0 | 2 |
| 366–730 days               | 1 | 1 | 6 | 1 | 0 | 2 |
| >730 days                  | 1 | 1 | 6 | 1 | 0 | 2 |

| Allograft failure (%)      | n | n | n | n | n | n |
|----------------------------|---|---|---|---|---|---|
| 0–60 days                  | 3 | 3 | 6 | 1 | 0 | 2 |
| 61–180 days                | 1 | 1 | 6 | 1 | 0 | 2 |
| 181–365 days               | 1 | 1 | 6 | 1 | 0 | 2 |
| 366–730 days               | 1 | 1 | 6 | 1 | 0 | 2 |
| >730 days                  | 1 | 1 | 6 | 1 | 0 | 2 |

| Allograft functioning (%)  | n | n | n | n | n | n |
|----------------------------|---|---|---|---|---|---|
| 0–60 days                  | 3 | 3 | 6 | 1 | 0 | 2 |
| 61–180 days                | 1 | 1 | 6 | 1 | 0 | 2 |
| 181–365 days               | 1 | 1 | 6 | 1 | 0 | 2 |
| 366–730 days               | 1 | 1 | 6 | 1 | 0 | 2 |
| >730 days                  | 1 | 1 | 6 | 1 | 0 | 2 |

| Including death with failed allograft (%) | n | n | n | n | n | n |
|-------------------------------------------|---|---|---|---|---|---|
| 0–60 days                                 | 3 | 3 | 6 | 1 | 0 | 2 |
| 61–180 days                               | 1 | 1 | 6 | 1 | 0 | 2 |
| 181–365 days                              | 1 | 1 | 6 | 1 | 0 | 2 |
| 366–730 days                              | 1 | 1 | 6 | 1 | 0 | 2 |
| >730 days                                 | 1 | 1 | 6 | 1 | 0 | 2 |

### Acknowledgments

The data reported in this study were supplied by the Australian and New Zealand Dialysis and Transplant Registry. The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the Australian and New Zealand Dialysis and Transplant Registry.

### References

1. Australian and New Zealand Organ Donation Registry. ANZOD Annual Report 2010. Available at https://www.anzodata.org.au/report/anzod-annual-report-2010. Accessed November 9, 2020.
2. Chapman JR, Kanelis J. Kidney donation and transplantation in Australia: more than a supply and demand equation. Med J Aust. 2018;209:242–243.
3. Pippais M, Stel VS, Arnol M, et al. Temporal trends in the quality of deceased donor kidneys and kidney transplant outcomes in Europe: an analysis by the ERA-EDTA Registry. Nephrol Dial Transplant. 2021;37:175–186.
4. Rao PS, Schaubel DE, Guidinger MK, et al. A comprehensive risk quantification score for deceased donor kidneys: the kidney donor risk index. Transplantation. 2009;88:231–236.
5. Dahmen M, Becker F, Pavenstädt H, et al. Validation of the Kidney Donor Profile Index (KDPI) to assess a deceased donor’s kidney’s outcome in a European cohort. Sci Rep. 2019;9:11234.
6. Arias-Cabrales G, Pérez-Sáez M.J, Redondo-Pachón D, et al. Usefulness of the KDPI in Spain: a comparison with donor age and definition of standard/expanded criteria donor. Nefrologia (Engl Ed). 2018;38:503–513.
7. Clayton PA, Dansie K, Sypek MP, et al. External validation of the US and UK kidney donor risk indices for deceased donor kidney transplant survival in the Australian and New Zealand population. Nephrol Dial Transplant. 2019;34:2127–2131.
8. Gandolfi I, Buzzo C, Zanelli P, et al. The Kidney Donor Profile Index (KDPI) of marginal donors allocated by standardized pretransplant donor biopsy assessment: distribution and association with graft outcomes. Am J Transplant. 2014;14:2515–2525.
9. Pruett TL, Vece GR, Carrico RJ, et al. US deceased kidney transplantation: estimated GFR, donor age and KDPI association with graft survival. Clinical Medicine. 2021;37:100981.
10. Hanharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int. 2002;62:311–318.
11. Keong FM, Afshar YA, Pastan SO, et al. Decreasing estimated glomerular filtration rate is associated with increased risk of hospitalization after kidney transplantation. Kidney Int Rep. 2016;1:269–278.
12. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation. 2002;75:1291–1295.
13. Pravettoni G, Bellini M, Cittadini A, et al. A guide to the Kidney Donor Profile Index. Transplantation. 2009;88:231–236.
14. Transplant Society of Australia and New Zealand. A guide to the Australian Kidney Donor Profile Index. 2016. Available at https://www.tsanz.com.au/storage/documents/AustralianKDPIINFOv10.pdf. Accessed November 9, 2020.
15. Transplantation Society of Australia and New Zealand. Australian KDPI calculator. Version 2016 – 2018. Available at https://www.tsanz.com.au/standalones/pages/document-download.asp. Accessed October 8, 2020.
16. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80:17–28.

17. Lehner LJ, Kleinsteuber A, Halleck F, et al. Assessment of the kidney donor profile index in a European cohort. Nephrol Dial Transplant. 2018;33:1465–1472.

18. Bae S, Massie AB, Thomas AG, et al. Who can tolerate a marginal kidney? Predicting survival after deceased donor kidney transplant by donor-recipient combination. Am J Transplant. 2019;19:425–433.

19. Sandal S, Luo X, Massie AB, et al. Machine perfusion and long-term kidney transplant recipient outcomes across allograft risk strata. Nephrol Dial Transplant. 2018;33:1251–1259.

20. Chan S, Campbell SB, Clayton PA, et al. Temporal changes in deceased kidney donor characteristics in Australia. Transplant Direct. 2016;2:e112.

21. Lam NN, Tonelli M, Lentine KL, et al. Albuminuria and posttransplant chronic kidney disease stage predict transplant outcomes. Kidney Int. 2017;92:470–476.

22. Karthikeyan V, Karpinski J, Nair RC, et al. The burden of chronic kidney disease in renal transplant recipients. Am J Transplant. 2003;4:262–269.

23. Syple MP, Hughes P, Holdsworth R, et al. Insights into the labeling effect of kidney donor performance index reporting: the Australian experience. Am J Transplant. 2020;20:870–878.

24. Bae S, Massie AB, Luo X, et al. Changes in discard rate after the introduction of the Kidney Donor Profile Index (KDPI). Am J Transplant. 2016;16:2202–2207.

25. Jay CL, Washburn K, Dean PG, et al. Survival benefit in older patients associated with earlier transplant with high KDPI kidneys. Transplantation. 2017;101:867–872.

26. ANZOD. Annual Report 2015. Available at https://www.anzdata.org.au/report/1135/. Accessed October 10, 2021.

27. Tullius SG, Tran H, Gulera I, et al. The combination of donor and recipient age is critical in determining host immunoresponsiveness and renal transplant outcome. Ann Surg. 2010;252:662–674.

28. Chopra B, Sureshkumar KK. Kidney transplantation in older recipients: preemptive high KDPI kidney vs lower KDPI kidney after varying dialysis vintage. World J Transplant. 2018;8:102–109.

29. Doshi MD, Reese PP, Hall IE, et al. Utility of applying quality assessment tools for kidneys with KDPI ≥80. Transplantation. 2017;101:1125–1133.